$SLS: Bull case, bear case, and the level that changes the read
The consensus on SELLAS Life Sciences Group, Inc. Common Stock is loud and, by my read, wrong. The evidence, the level that settles it, and where I'd admit defeat.

Listen: hear this article read aloud (about 3 min).
Here is what is at stake in SELLAS Life Sciences Group, Inc. Common Stock: $12.44 if the read is right, $6.72 if it isn't. Everything else on this page is commentary.
The crowd has SELLAS Life Sciences Group, Inc. Common Stock wrong. Not slightly wrong, directionally wrong, and the tape has been saying so for a while.
Somebody is still shorting SELLAS Life Sciences Group, Inc. Common Stock into this, and the FINRA data doesn't care about anyone's opinion. It counts.
$SLS sits at $7.47, $4.97 below its 20-day high of $12.44 and $0.33 above its 20-day low of $7.14.
My read: neutral, waiting on confirmation. I want confirmation before I call a direction.
A short that will not fall
Against its own 60-session range, $SLS is 52.0% below the high of $15.56 (Aug 27) and 4.6% above the low of $7.14 (Nov 6).
$SLS closed higher in 4 of its last 9 sessions. Volume over the last five sessions averaged 0.8x the twenty sessions before them. The largest one-day move in the past twenty sessions was -14.7% on Oct 28.
63% of SLS's off-exchange volume printed as short sales (FINRA daily short volume), against a normal 58%.
Days to cover: 6.7. Every short in the name needs 6.7 full days of normal volume to get out.
What I make of it: a crowded short matters only if the stock stops falling, and then covering becomes buying. Whether that starts here is the whole question.
So what is the market actually pricing in? That is the next question.
What is already in the price
Off-exchange trading: QUIET: no block prints, 43% off-exchange. No block-size prints (10,000+ shares or $1M+) in this window. Off-exchange volume is spread across small prints, which is what internalized retail flow looks like. Days to cover 6.7, 57.1M shares short, short interest +6.3% since the last report. Squeeze risk 18 of 100; shorts pressing 83 of 100.
Across the broader market, the read is Neutral (bias -7).
Sentiment readings show neutral (-8 of 100). Insiders: quiet.
What I make of it: the pieces mostly point the same way as the price, which is more than I can say for most setups. None of them is proof.
None of which is the detail that changes the read. That comes next.
The bull case
- Short squeeze setup with a measured path to $12.44
The bear case
- Backdrop: Neutral (bias -7)
- Borrow cost decides who exits first
The detail that changes the read
What I think traders are overlooking is the volume. Price can drift to a level on almost nothing, and what it does there needs real participation. Without it, a break is easy to fade.
That part doesn't show up on the chart.
The call, and the line that breaks it
If $SLS posts a close above the recent high on rising volume and volume expands, I think $12.44 becomes the next serious test. Under $6.72, I'm wrong.
The honest objection is that short volume is not a short position. A high ratio is routine in liquid names, and sometimes the shorts are simply right.
So the plan is simple. Wait for the level, wait for the volume, and respect the line.
What the consensus is missing
The popular read on SELLAS Life Sciences Group, Inc. Common Stock is simple: it has run too far and the next move is down. It is the kind of read that sounds right because everyone is repeating it, and that is the first thing wrong with it.
Here is what it skips. The buyers have not left: price is holding its ground while the sceptics get the headlines, and a floor that holds under pressure is not what a top looks like. My read is the opposite of the crowd's, and $6.72 is the line that settles the argument.
I would rather be early and specific than agreeable and vague. If the sceptics are right, I'm out at $6.72 and I will say so. If they are wrong, $12.44 is where the argument ends.
What else the data shows
Market cap about $1.5B. The stock is already running: shorts are losing, not waiting. Market backdrop: Neutral (bias -7).
Liquidity map levels: $8.37 (supply block), $7.83 (equal lows (stops below)), $8.10 (equal highs (stops above)), $7.32 (bullish gap).
Dark pool: QUIET: no block prints, 43% off-exchange. No block-size prints (10,000+ shares or $1M+) in this window. Off-exchange volume is spread across small prints, which is what internalized retail flow looks like. For a long: not a squeeze: shorts are pressing a weak tape (trap 60); do not buy because it is "heavily shorted".
For a short seller: press: sellers are in control and the short crowd is not trapped, but keep the stop tight: 6.7 days to cover can squeeze on any catalyst. MEM ALGO's short model has an open SELL (grade B).. Crowd sentiment: neutral (-8 of 100).
Three ways this goes
The base case: $SLS works through a close above the recent high on rising volume on volume and makes its way toward $12.44 over 1 to 3 weeks. That is the path the setup is built for, and it needs participation to stay honest.
The faster case: the move comes early and overshoots the target before the horizon is up. I would not chase that; I would let the level be retested.
The failure case: $6.72 gives way and the thesis ends where it started. No averaging down, no renaming it.
The timeline
First, the trigger: a close above the recent high on rising volume. Nothing counts until that prints.
Then the confirmation: a second day of 63%-plus short volume with price refusing to fall: shorts pressing into strength. Without it the trigger was noise.
Then the target, $12.44, and the decision at it: take the move, or let the next level set up. Through it all, $6.72 is the line that ends the trade.
Kill switch
Any one of these and the thesis is over, no averaging down, no renaming it.
- A close through $6.72.
- Selling absorbs the buying at a key level and price loses it on volume.
- Order flow reverses: the sweeps and blocks turn to the other side.
- A scheduled event changes the picture before the trigger is reached.
Questions readers ask
Is $SLS a buy right now? Nobody honest answers that for you. The data says $SLS is a bullish short squeeze candidate with a scenario target of $12.44 (+66.5%) and an invalidation at $6.72. Whether that fits your account, your horizon and your risk is your call, not ours.
What is the $SLS price target in this read? The scenario target is $12.44, +66.5% from $7.47, over 1 to 3 weeks. It is where the setup runs out of fuel if it works, not a forecast and not a recommendation.
What would prove the $SLS short squeeze thesis wrong? A close back under the 20-day average with short volume drying up: the shorts were right. If that happens, the read is wrong and the idea should not exist anymore.
How heavily shorted is SELLAS Life Sciences Group, Inc. Common Stock? The latest reported days-to-cover figure is 6.7. 63% of recent off-exchange volume printed as short sales on the FINRA feed. Short interest is reported twice a month; short volume is daily, and the two measure different things.
Where I land
I'll take the unpopular side of SELLAS Life Sciences Group, Inc. Common Stock and put a line under it. $6.72 and I'm wrong. $12.44 and the crowd was.
Desk record. 44 of 278 scenario targets traded before their invalidation (16%), 163 stopped out, 71 ran out of time, average outcome -0.04% per piece. Past pieces say nothing about this one.
The desk's scenario leans bullish. Bull or bear, the kill switch above is what keeps either view honest.
Sources and further reading: SEC EDGAR filings for SLS · FINRA daily short sale volume files · Nasdaq short interest: SLS · SELLAS Life Sciences Group, Inc. Common Stock investor site · SLS quote, chart and data on StockMarketLoop.
Data as of Nov 17, 8:21 AM ET: options positioning, FINRA short volume, the off-exchange trade record, the structure map, SEC filings and the ticker's headlines. Vaughn McNair (Grandmaster-Obi) and Making Easy Money may hold or trade positions in the names discussed. This is speculation and education, not financial advice.

Sign up now to get access to the library of members-only issues.
Free. Confirm by email. One click to leave.
Discussion (0)